Robust CCI verification is essential not only for regulatory compliance but also for protecting product stability and patient safety. As advanced therapies become more complex, the rigor and precision of CCI testing will remain indispensable.
Wednesday, April 29, 2026
The cell therapy sector remains constrained by particulate guidance based on traditional parenteral products, says a BioPhorum publication.
Wednesday, April 15, 2026
Cultivating resilient, stage-appropriate supply strategies is an essential yet often overlooked part of delivering safe, effective therapies to patients.
Wednesday, April 01, 2026
New findings establish the feasibility of combining nonviral ex vivo gene editing, hepatocyte transplantation, and in vivo selection, and support the clinical translation of cell-based gene-editing therapies for inherited metabolic liver diseases.
Wednesday, March 25, 2026
We are living in the golden age of cell and gene therapy — but the spoils will go to those who chart a deliberate course, choose the right partners, and translate breakthrough science into sustainable commercial reality.
A well-designed development roadmap can be a powerful strategic asset — shaping investor confidence and guiding capital deployment. Yet questions persist around the optimal timing for roadmap buildout and how it should evolve alongside preclinical development activities and fundraising efforts.
The evolution from imitation to innovation has created an ecosystem designed to reward novel science and transformative treatment approaches — and Swiss companies are now claiming their stake.
Tuesday, February 24, 2026
Rare and ultra-rare disease patients have long been forced to struggle upstream.
Wednesday, February 18, 2026
As advanced therapies transition from promising science to industrial maturity, investors will increasingly favor late-stage programs with strong data, proven scalability and credible paths to adoption.
Monday, February 09, 2026
A decentralized model for cell-based products offers various benefits including fresh tissues and drug products, reduced costs, and shorter treatment times.
Wednesday, February 04, 2026